Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy of Nebulized Procaterol Versus Nebulized Salbutamol for the Treatment of Moderate Acute Asthma: a Randomized, Double-blind, Parallel Group Study.

Next Previous
Trial Profile

The Efficacy of Nebulized Procaterol Versus Nebulized Salbutamol for the Treatment of Moderate Acute Asthma: a Randomized, Double-blind, Parallel Group Study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Procaterol (Primary) ; Salbutamol
  • Indications Acute asthma
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical

Most Recent Events

  • 01 Oct 2011 Primary endpoint 'Peak-expiratory-flow-rate' has not been met. Difference between treatment groups (3.9%) reached statistical significance (p<0.05) but did not reach pre-specified clinical significance criteria (5%).
  • 08 Oct 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
  • 12 Aug 2009 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top